· First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening· Available as small gene families, bespoke collections, the druggable genome, or human genome-wide collection
29 March, 2018
EU conference and two-day ‘hack the lab’ hackathon discusses how artificial intelligence (AI) and the Internet of Things (IoT) will impact life sciences
20 March, 2018
The Phenomics Discovery Initiative (PDi) has expanded its assay portfolio to a total of 11 complex phenotypic assays that are relevant to human pathophysiology in areas of unmet clinical need including neuropsychiatric illnesses, dementia, cancer and respiratory infections.
08 March, 2018
BC Platforms, a world leader in genomic data management and analytics, announces that it has been selected by Gene By Gene, the industry leader in offering integrated multi-disciplinary genetic testing services, to scale up its genomic data processing and storage capabilities.
07 March, 2018
BC Platforms, a pioneer in genomic data management and analytics, today announces it has launched GeneVision, a new end-to-end Solution for Precision Medicine, that uses the Microsoft Genomics service which runs on Microsoft Azure. GeneVision provides end-to-end Software-as-a-Service solution from raw genome data to patient reports, implemented using Azure services. GeneVision utilizes several of BC Platforms existing pipeline technologies, and offers scalable, easy-to-use workflows for both genotyping and next generation sequencing, data quality monitoring, and production of different patient reports for precision medicine.
06 March, 2018
“It seems like every time you turn around, someone is talking about the importance of artificial intelligence and machine learning,” said Trey Ideker, PhD, University of California San Diego School of Medicine and Moores Cancer Center professor. “But all of these systems are so-called ‘black boxes.’ They can be very predictive, but we don’t actually know all that much about how they work.”
06 March, 2018
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The Flemish biotech spin-off Aelin Therapeutics will exploit the technology to produce new antibiotics for the clinic.
01 March, 2018